Integrin signaling represents a promising but emerging therapeutic target for Parkinson's disease (PD). While no companies have advanced integrin-specific therapies into clinical trials for PD specifically, several companies have programs targeting related pathways including focal adhesion kinase (FAK), integrin-linked kinase (ILK), and cell adhesion mechanisms that intersect with neurodegenerative processes. This page catalogs companies working on integrin-related approaches and relevant research.
| Direct Integrin Agonists | Research only |
|---|---|
| FAK Modulators | Preclinical |
| ILK Inhibitors | Research only |
| Cell Adhesion Therapies | Preclinical |
Several major pharmaceutical companies with PD programs work on pathways that intersect with integrin signaling, particularly LRRK2 (leucine-rich repeat kinase 2) which regulates integrin-dependent signaling [1].
Headquarters: South San Francisco, California, USA
Ticker: NASDAQ: DNLI
Focus: Biopharmaceuticals for neurodegenerative diseases
Denali Therapeutics is leading the development of LRRK2 inhibitors for Parkinson's disease. While not targeting integrins directly, LRRK2 signaling intersects with integrin pathways through multiple mechanisms:
The LRRK2-integrin connection is supported by research showing that PD-linked LRRK2 mutations affect integrin signaling pathways 2. Denali's programs may indirectly modulate integrin-dependent neuroprotection.
Pipeline:
| Drug | Mechanism | Phase | Status |
|---|---|---|---|
| DNL151 (BIIB122) | LRRK2 inhibitor | Phase 1b | Completed |
| DNL343 | LRRK2 inhibitor | Phase 1 | Active |
Headquarters: Cambridge, Massachusetts, USA
Ticker: NASDAQ: BIIB
Focus: Neurodegenerative disease therapies
Biogen has an active Parkinson's disease pipeline through its partnership with Denali Therapeutics on LRRK2 inhibitors:
Biogen collaborates with academic groups studying integrin-FAK pathways in dopaminergic neurons, though no public integrin-specific programs exist yet.
Headquarters: Basel, Switzerland
Ticker: SIX: RO
Focus: Neuroscience
Roche has an active neuroscience division with PD programs:
While not publicly disclosed, Roche's broad neuroscience research may include integrin-related pathways.
Several companies provide research tools and platform technologies relevant to integrin drug discovery:
| Company | Technology | Relevance |
|---|---|---|
| ChemieTek | Small molecule libraries | FAK inhibitor screening compounds |
| MedChemExpress | Research chemicals | Integrin ligand mimetics |
| Tocris/Bio-Techne | Biological reagents | Integrin research tools |
| R&D Systems | Proteins | Integrin subunit research |
The integrin-PD field remains primarily academic, with most advances coming from research institutions:
Integrin-targeting drugs are approved for other conditions, demonstrating clinical viability 3:
| Drug | Target | Indication | Company | Status |
|---|---|---|---|---|
| Natalizumab | α4 integrin | Multiple sclerosis | Biogen/Elan | Approved |
| Abciximab | αIIbβ3 | Anti-platelet | Eli Lilly | Approved |
| Vedolizumab | α4β7 | IBD | Takeda | Approved |
| Lifitegrast | LFA-1 | Dry eye | Novartis | Approved |
These precedents demonstrate that integrin modulation is clinically feasible. Repurposing or analog development for CNS indications remains an opportunity.
Focal adhesion kinase (FAK) is a central mediator of integrin signaling. FAK modulators in development include:
Rather thanBlocking integrins, activating integrins may support neuronal survival:
Microglial integrins drive neuroinflammation in PD. Targeting these may reduce pathology 5:
Several companies have platforms that could be applied to integrin-PD therapies:
Focus: Phenotypic screening and computational biology
Recursion uses phenotypic screening to identify therapeutic candidates across multiple disease areas including neurodegeneration. Their approach could identify integrin modulators through unbiased phenotypic screening.
Focus: Neurodegeneration
Vincere Biosciences focuses on molecular targets in neurodegeneration with an emphasis on protein homeostasis and cell stress pathways. Integrin-dependent cell adhesion may be relevant to their platform.
Focus: Protein engineering
Manifold Bio's protein engineering capabilities could be applied to developing integrin-targeting therapeutic antibodies or engineered proteins.